Clinical Research
Coronary
Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial

https://doi.org/10.1016/j.jcin.2015.01.031Get rights and content
Under an Elsevier user license
open archive

Abstract

Objectives

This study sought to investigate the long-term comparative efficacy and safety of paclitaxel-eluting balloon (PEB), paclitaxel-eluting stent (PES), or balloon angioplasty (BA) for the treatment of drug-eluting stent restenosis.

Background

The optimal treatment of drug-eluting stent restenosis remains unknown. Although PEB has shown encouraging results, the long-term clinical efficacy and safety of PEB remains poorly defined.

Methods

A total of 402 patients with clinically significant restenosis in limus-eluting stents were randomly assigned to receive PEB (n = 137), PES (n = 131), or BA (n = 134). For this analysis, PEB versus PES and PEB versus BA were compared. The primary efficacy and safety endpoints were target lesion revascularization and the composite of death or myocardial infarction.

Results

At a median follow-up of 3 years, the risk of target lesion revascularization was comparable with PEB versus PES (hazard ratio [HR]: 1.46, 95% confidence interval [CI]: 0.91 to 2.33; p = 0.11) and lower with PEB versus BA (HR: 0.51, 95% CI: 0.34 to 0.74; p < 0.001). The risk of death/myocardial infarction tended to be lower with PEB versus PES (HR: 0.55, 95% CI: 0.28 to 1.07; p = 0.08), due to a lower risk of death (HR: 0.38, 95% CI: 0.17 to 0.87; p = 0.02). The risk of death/myocardial infarction was similar with PEB versus BA (HR: 0.96, 95% CI: 0.46 to 2.0; p = 0.91).

Conclusions

At 3 years, the use of PEB as compared with PES to treat patients with limus-eluting stent restenosis has similar efficacy and safety. PEB remains superior to BA. The sustained efficacy without trade-off in safety supports the role of PEB as treatment option for patients with drug-eluting stent restenosis. (Intracoronary Stenting and Angiographic Results: Drug Eluting Stent In-Stent Restenosis: 3 Treatment Approaches [ISAR-DESIRE 3]; NCT00987324)

Key Words

balloon angioplasty
drug-eluting stent restenosis
paclitaxel-eluting balloon
paclitaxel-eluting stent

Abbreviations and Acronyms

BA
balloon angioplasty
CI
confidence interval
DES
drug-eluting stent(s)
HR
hazard ratio
MI
myocardial infarction
PEB
paclitaxel-eluting balloon
PES
paclitaxel-eluting stent(s)
TLR
target lesion revascularization

Cited by (0)

Dr. Kastrati has been issued or has applied for patents related to stent technology. Dr. Byrne has received lecture fees from B. Braun Melsungen and Biotronik. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Kufner and Cassese contributed equally to this work.